Search clinical trials for: JCARH125

Total 6 results

Juno Therapeutics, a Subsidiary of Celgene

Terminated

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Follicular Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

United States
Juno Therapeutics, a Subsidiary of Celgene

Completed

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Juno Therapeutics, a Subsidiary of Celgene

Completed

Long-Term Follow-up Study for Patients Previously Treated With JCAR015

Acute Lymphoblastic Leukemia

United States
Celgene
Juno

Withdrawn

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia (ORBIT)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Belgium, France, Spain, Italy, Germany, Switzerland, United Kingdom
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)

Acute Lymphoblastic Leukemia

United States

3

Subscribe